title: Effects of moxonidine on sympathetic nervous system activity: An update on metabolism, cardio, and other target-organ protection.
abstract: Moxonidine is the newest, second-generation, centrally acting antihypertensive agent. It has selective agonist activity at imidazoline I1 receptors and less adverse effects than the other centrally acting drugs. This fact authorizes the frequent use of moxonidine in clinical practice, as monotherapy or in combination with other antihypertensive agents. Also, moxonidine has beneficial effects in obese and metabolic syndrome and in target-organs, such as heart and kidneys.
authors.affiliation: Department of Internal Medicine, AHEPA Hospital, Thessaloniki, Greece.
authors.forename: Eleni F
authors.initials: EF
authors.lastname: Karlafti
authors.forename: Apostolos I
authors.initials: AI
authors.lastname: Hatzitolios
authors.forename: Anastasios F
authors.initials: AF
authors.lastname: Karlaftis
authors.forename: Maria S
authors.initials: MS
authors.lastname: Baltatzi
authors.forename: Georgios G
authors.initials: GG
authors.lastname: Koliakos
authors.forename: Christos G
authors.initials: CG
authors.lastname: Savopoulos
keywords: Moxonidine; organ protection; sympathetic nervous system